Copyright
©The Author(s) 2017.
World J Gastroenterol. Feb 28, 2017; 23(8): 1489-1496
Published online Feb 28, 2017. doi: 10.3748/wjg.v23.i8.1489
Published online Feb 28, 2017. doi: 10.3748/wjg.v23.i8.1489
Figure 3 Comparison of the infliximab trough levels between patients with/without antibody to infliximab.
In the ATI-negative and -positive groups, the median infliximab trough levels (IFX-TLs) were 1.415 μg/mL (IQR 0.570-2.495) and 0.141 μg/mL (IQR 0.002-0.869), respectively (P < 0.001). ATI: Antibodies to infliximab.
- Citation: Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease. World J Gastroenterol 2017; 23(8): 1489-1496
- URL: https://www.wjgnet.com/1007-9327/full/v23/i8/1489.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i8.1489